Six Distinct Subtypes of Depression, Anxiety Identified Via Brain Imaging
Medscape | By Megan Brooks
Brain imaging combined with artificial intelligence has identified six distinct "biotypes" of depression and anxiety that may lead to more personalized and effective treatment.
This research has "immediate clinical implications," study investigator Leanne Williams, PhD, director of the Stanford Medicine Center for Precision Mental Health and Wellness, told Medscape Medical News.
"At Stanford, we have started translating the imaging technology into use in a new precision mental health clinic. The technology is being actively developed for wider use in clinical settings, and we hope to make it accessible to more clinicians and patients," Williams said.
No More Trial and Error?
Depression is a highly heterogeneous disease, with individual patients having different symptoms and treatment responses. About 30% of patients with major depression are resistant to treatment, and about half of patients with generalized anxiety disorder do not respond to first-line treatment.
"The dominant 'one-size-fits-all' diagnostic approach in psychiatry leads to cycling through treatment options by trial and error, which is lengthy, expensive, and frustrating, with 30-40% of patients not achieving remission after trying one treatment," the authors noted.
"The goal of our work is figuring out how we can get it right the first time," Williams said in a news release, and that requires a better understanding of the neurobiology of depression.
To that end, 801 adults diagnosed with depression and anxiety underwent functional MRI to measure brain activity at rest and when engaged in tasks designed to test cognitive and emotional functioning.
Researchers probed six brain circuits previously associated with depression: The default mode circuit, salience circuit, attention circuit, negative affect circuit, positive affect circuit, and the cognitive control circuit.
Using a machine learning technique known as cluster analysis to group the patients' brain images, they identified six clinically distinct biotypes of depression and anxiety defined by specific profiles of dysfunction within both task-free and task-evoked brain circuits.
"Importantly for clinical translation, these biotypes predict response to different pharmacological and behavioral interventions," investigators wrote.
For example, patients with a biotype characterized by overactivity in cognitive regions of the brain experienced the best response to the antidepressant venlafaxine compared with patients with other biotypes…
Read Full Article |